REFERENCES
- Bishara, D., & Taylor, D. (2008). Upcoming agents for the treatment of schizophrenia:Mechanism of action, efficacy, and tolerability. Drugs, 68(16), 2269–2292.
- Caccia, S., Pasina, L., & Nobile, A. (2010). New atypical antipsychotics for schizophrenia: Iloperidone. Drug Design, Development and Therapy, 4, 33–48.
- Cutler, A. J., Kalali, A. H., Weiden, P. J., Hamilton, J., & Wolfgang, C. D. (2008). Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of Clinical Psychopharmacology, 28(2 Suppl 1), S20–28.
- Kane, J. M., Lauriello, J., Laska, E., Di Marino, M., & Wolfgang, C. D. (2008). Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Journal of Clinical Psychopharmacology, 28(2 Suppl 1), S29–S35.
- Kay, S. R., Opler, L. A., & Lindenmayer, J. P. (1988). Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics * 1. Psychiatry Research, 23(1), 99–110.
- Marino, J., & Caballero, J. (2010). Iloperidone for the treatment of schizophrenia. Annals of Pharmacotherapy, 44(5), 863–870.
- McIntyre, R. S., Cohen, M., Zhao, J., Alphs, L., Macek, T. A., & Panagides, J. (2010). Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial. Journal of Affective Disorders, 122, 27–38.
- McIntyre, R. S., Cohen, M., Zhao, J., Alphs, L., Macek, T. A., & Panagides, J. (2009). Asenapine versus olanzapine in acute mania: A double-blind extension study. Bipolar Disorders, 11, 815–826.
- Weber, J., & McCormick, P. L. (2009). Asenapine. CNS Drugs, 23(9), 781–792.
- Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978). Arating scale for mania: Reliability, validity, and sensativity. The British Journal of Psychiatry, 133(5), 429–435.